ArticleCureus2024
Delayed Diagnosis of Primary Ciliary Dyskinesia in Low-Middle-Income Countries: The Clinical Value of Nasal Nitric Oxide.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Primary Ciliary Dyskinesia: A Suggested Pathway to Transition From Pediatric to Adult Care.Pediatric pulmonology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary ciliary dyskinesia (PCD) is a rare lung disease that causes chronic oto-sino-pulmonary disease with irreversible lung damage. Several diagnostic methods exist, but electron microscopy (EM) is the most accurate tool, as it visualizes alterations in the axonemal ultrastructure; however, some patients may present a normal ciliary structure. Therefore, other diagnostic methods have been promoted, such as genetic studies or immunofluorescence of specific markers; nonetheless, they are not very accessible and expensive and even present a high level of false negatives. The quantification of nasal nitric oxide (nNO) has been a well-known tool for decades for the screening of this pathology, and recent studies have highlighted its high predictive value in the diagnosis of PCD, as it is a rapid tool in its processing, execution, and accessibility, especially in countries with limited health resources. We present the case of a patient with respiratory symptoms since childhood and extensive lung damage (cystic bronchiectasis); due to lack of access to EM or immunofluorescence, determinations of nNO were performed and found to be compatible with PCD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.